Pradžia › Inksto nepakankamumas › Arizona
Inksto nepakankamumas klinikiniai tyrimai Arizona
6 tyrimai dėl Inksto nepakankamumas ieško dalyvių vietose Arizona.
Miestai Arizona
Oficialus tyrimo tekstas (anglų kalba)
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
- Arizona Clinical Trials - Chandler, Chandler
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 84 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07763418Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- AKDHC Medical, Glendale
- Kidney Disease Medical Group, Glendale
- AKDHC Medical, Phoenix
- ir dar 2
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT05485961REgulatory T Cell Therapy to Achieve Immunosuppression REduction
- Mayo Clinic in Arizona, Phoenix
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-04-27 · NCT06552169Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
- Southwest Kidney Institute, Phoenix
- AKDHC Medical Research Services, Phoenix
- AKDHC Center Tucson, Tucson
Renkami dalyviai
Amžius nuo 18 iki 84 · Visoms lytims · Atnaujinta 2026-04-13 · NCT06190717SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
- AKDHC Bullhead City, Bullhead City
- AKDHC Marana Surgery Center, Marana
- Arizona Kidney Disease & Hypertension Centers (AKDHC) Phoenix Surgery Center, Phoenix
- ir dar 1
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-17 · NCT06001827A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- AKDHC Medical Research Services, LLC, Phoenix
Renkami dalyviai
Amžius nuo 18 iki 90 · Visoms lytims · Atnaujinta 2025-12-22 · NCT04671771Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.